Female Breast Cancer disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: FML037 MIFTS: 52	Female Breast Cancer Categories: Cancer diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Female Breast Cancer

MalaCards integrated aliases for Female Breast Cancer:

Name: Female Breast Cancer ¹¹ ¹⁴

Female Breast Carcinoma ¹¹ ¹⁴ ⁷¹

Malignant Neoplasm of Female Breast ⁷¹

Mammary Carcinoma of Female Breast ¹¹

Carcinoma of Female Breast ¹¹

Classifications:

MalaCards categories:
Global: Cancer diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹¹ DOID:0050671 DOID:7843

NCIt ⁴⁹ C2918

UMLS ⁷¹ C0007104 C0235653

Sources

Summaries for Female Breast Cancer

Disease Ontology ¹¹ Female breast cancer: A breast cancer that develops from breast tissue in females.

Female breast carcinoma: A breast carcinoma that is manifested in the female breast.

MalaCards based summary: Female Breast Cancer, also known as female breast carcinoma, is related to tubular adenocarcinoma and breast-ovarian cancer, familial 2. An important gene associated with Female Breast Cancer is PGR (Progesterone Receptor), and among its related pathways/superpathways are Gene expression (Transcription) and ERK Signaling. The drugs Toremifene and Sevoflurane have been mentioned in the context of this disorder. Affiliated tissues include breast, lymph node and prostate, and related phenotypes are Increased cell death in HCT116 cells and homeostasis/metabolism

Sources

Related Diseases for Female Breast Cancer

Diseases related to Female Breast Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 519)

#	Related Disease	Score	Top Affiliating Genes
1	tubular adenocarcinoma	30.4	PGR ESR1 ERBB2 CTSD
2	breast-ovarian cancer, familial 2	30.4	BRCA2 BRCA1
3	hereditary breast cancer	30.4	BRCA2 BRCA1
4	progesterone-receptor positive breast cancer	30.3	PGR ESR1 ERBB2 CYP19A1
5	mammary paget's disease	30.1	PIP PGR ESR1 ERBB2 AR
6	ovarian cyst	30.0	PGR ESR2 ESR1 CYP19A1 BRCA1
7	skin carcinoma	30.0	TP53 KRT5 ERBB2 EGFR CDK4 BCL2
8	cervix carcinoma	30.0	TP53 PGR ESR1 ERBB2 EGFR BCL2
9	breast disease	29.9	TP53 PGR KLK3 ESR2 ESR1 ERBB2
10	sporadic breast cancer	29.9	TP53 PGR KRT5 ESR1 ERBB2 BRCA2
11	adenoid cystic carcinoma	29.9	TP53 PGR ERBB2 EGFR CDK4 BRCA1
12	melanoma, uveal	29.9	TP53 ERBB2 EGFR CDK4 BRCA1 BCL2
13	diabetes mellitus	29.9	TP53 KLK3 ESR2 ESR1 EGFR CYP19A1
14	inherited cancer-predisposing syndrome	29.8	TP53 MLH1 EGFR CDK4 BRCA2 BRCA1
15	bap1 tumor predisposition syndrome	29.8	TP53 MLH1 EGFR CDK4 BRCA2 BRCA1
16	infertility	29.8	PGR MLH1 ESR2 ESR1 CYP19A1 AR
17	gynecomastia	29.8	PGR KLK3 ESR2 ESR1 ERBB2 CYP19A1
18	hereditary breast ovarian cancer syndrome	29.8	TP53 PGR MLH1 ESR1 ERBB2 EGFR
19	breast fibroadenoma	29.7	TP53 PGR KRT5 ESR1 ERBB2 EGFR
20	peripheral nervous system disease	29.6	TP53 ESR1 ERBB2 EGFR CDK4 BRCA1
21	adenocarcinoma	29.6	TP53 MLH1 KLK3 ERBB2 EGFR CDK4
22	lynch syndrome	29.5	TP53 PGR MLH1 ESR1 ERBB2 EGFR
23	endometrial cancer	29.4	TP53 PGR MLH1 ESR2 ESR1 ERBB2
24	estrogen-receptor positive breast cancer	29.3	TP53 PGR ESR2 ESR1 ERBB2 EGFR
25	breast cancer	29.2	TP53 TOP2A PIP PGR MLH1 KRT5
26	ductal carcinoma in situ	29.2	TP53 PIP PGR KRT5 GATA3 ESR2
27	breast ductal carcinoma	29.0	TP53 PIP PGR KRT5 ESR2 ESR1
28	breast carcinoma in situ	29.0	TP53 PIP PGR KRT5 GATA3 ESR2
29	hepatocellular carcinoma	28.9	TP53 TOP2A PGR MLH1 ESR1 ERBB2
30	ovarian cancer	28.4	TP53 TOP2A PGR MLH1 KLK3 ESR2
31	prostate cancer	28.2	TP53 TOP2A PGR MLH1 KRT5 KLK3
32	female breast nipple and areola cancer	11.1
33	female breast central part cancer	11.1
34	female breast lower-outer quadrant cancer	11.1
35	female breast upper-inner quadrant cancer	11.1
36	female breast lower-inner quadrant cancer	11.1
37	female breast axillary tail cancer	11.1
38	female breast upper-outer quadrant cancer	11.1
39	uterine corpus adenosarcoma	10.5	PGR ESR1
40	scirrhous adenocarcinoma	10.4	PGR ERBB2
41	adult cystic nephroma	10.4	PGR ESR1
42	her2-receptor negative breast cancer	10.4	PGR ERBB2
43	vagina leiomyosarcoma	10.4	PGR ESR1
44	vulvar benign neoplasm	10.4	PGR ESR1
45	hereditary site-specific ovarian cancer syndrome	10.4	BRCA2 BRCA1
46	ovary transitional cell carcinoma	10.4	BRCA2 BRCA1
47	apocrine adenosis of breast	10.4	TP53 ERBB2
48	cancerophobia	10.4	BRCA2 BRCA1
49	subserous uterine fibroid	10.4	PGR CYP19A1
50	tetraploidy	10.4	TP53 BRCA2

Comorbidity relations with Female Breast Cancer via Phenotypic Disease Network (PDN):

Acute Cystitis	Breast Fibroadenosis
Deficiency Anemia	Fat Necrosis of Breast
Hypertension, Essential	Hypothyroidism
Mastitis	Microglandular Adenosis
Neutropenia

Graphical network of the top 20 diseases related to Female Breast Cancer:

Sources

Symptoms & Phenotypes for Female Breast Cancer

GenomeRNAi Phenotypes related to Female Breast Cancer according to GeneCards Suite gene sharing:

²⁵

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	no effect	GR00402-S-1	10.19	ANKRD30A AR BCL2 BRCA1 BRCA2 CDK4
2	no effect	GR00402-S-2	10.19	AR BCL2 BRCA1 BRCA2 CDK4 CTSD
3	Increased cell death in HCT116 cells	GR00103-A-0	8.65	TOP2A

MGI Mouse Phenotypes related to Female Breast Cancer:

⁴⁵ (show all 25)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.46	AR BCL2 BRCA1 BRCA2 CDK4 CTSD
2	endocrine/exocrine gland	MP:0005379	10.45	AR BCL2 BRCA1 BRCA2 CDK4 CTSD
3	growth/size/body region	MP:0005378	10.44	AR BCL2 BRCA1 BRCA2 CDK4 CTSD
4	normal	MP:0002873	10.42	AR BRCA1 BRCA2 CDK4 CYP19A1 EGFR
5	nervous system	MP:0003631	10.42	AR BCL2 BRCA1 BRCA2 CDK4 CTSD
6	neoplasm	MP:0002006	10.4	AR BCL2 BRCA1 BRCA2 CDK4 EGFR
7	muscle	MP:0005369	10.4	AR BCL2 BRCA1 CDK4 CYP19A1 EGFR
8	digestive/alimentary	MP:0005381	10.4	AR BCL2 BRCA1 BRCA2 CDK4 CTSD
9	cellular	MP:0005384	10.36	AR BCL2 BRCA1 BRCA2 CDK4 CTSD
10	renal/urinary system	MP:0005367	10.34	AR BCL2 BRCA1 CDK4 CYP19A1 EGFR
11	immune system	MP:0005387	10.3	AR BCL2 BRCA1 BRCA2 CDK4 CTSD
12	cardiovascular system	MP:0005385	10.28	AR BCL2 BRCA1 CDK4 CYP19A1 EGFR
13	limbs/digits/tail	MP:0005371	10.27	AR BRCA1 BRCA2 EGFR ERBB2 ESR1
14	embryo	MP:0005380	10.25	AR BCL2 BRCA1 BRCA2 CDK4 EGFR
15	pigmentation	MP:0001186	10.22	AR BCL2 BRCA1 CDK4 CYP19A1 EGFR
16	adipose tissue	MP:0005375	10.22	AR BCL2 BRCA1 CYP19A1 EGFR ESR1
17	behavior/neurological	MP:0005386	10.22	AR BCL2 BRCA1 BRCA2 CDK4 CTSD
18	reproductive system	MP:0005389	10.22	AR BCL2 BRCA1 BRCA2 CDK4 CYP19A1
19	liver/biliary system	MP:0005370	10.19	AR CDK4 CYP19A1 EGFR ESR1 ESR2
20	hearing/vestibular/ear	MP:0005377	10.09	BCL2 CTSD CYP19A1 EGFR ESR2 GATA3
21	hematopoietic system	MP:0005397	10.09	AR BCL2 BRCA1 BRCA2 CDK4 CTSD
22	craniofacial	MP:0005382	10.08	AR BCL2 CDK4 EGFR ERBB2 GATA3
23	skeleton	MP:0005390	10.03	AR BRCA1 BRCA2 CDK4 CYP19A1 EGFR
24	mortality/aging	MP:0010768	9.86	AR BCL2 BRCA1 BRCA2 CDK4 CTSD
25	integument	MP:0010771	9.55	AR BCL2 BRCA1 BRCA2 CDK4 CTSD

Sources

Drugs & Therapeutics for Female Breast Cancer

Drugs for Female Breast Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 86)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Toremifene

Approved, Investigational

Phase 4

89778-26-7

3005573

Sevoflurane

Approved, Vet_approved

Phase 4

28523-86-6

5206

Propofol

Approved, Investigational, Vet_approved

Phase 4

2078-54-8

4943

Estrogen Receptor Modulators

Phase 4

Selective Estrogen Receptor Modulators

Phase 4

Platelet Aggregation Inhibitors

Phase 4

Anesthetics, Intravenous

Phase 4

Anesthetics, Inhalation

Phase 4

Anesthetics, General

Phase 4

Anesthetics

Phase 4

Hypnotics and Sedatives

Phase 4

Fulvestrant

Approved, Investigational

Phase 3

129453-61-8

17756771 104741

Anastrozole

Approved, Investigational

Phase 3

120511-73-1

2187

Goserelin

Approved

Phase 3

65807-02-5

5311128 47725

Letrozole

Approved, Investigational

Phase 3

112809-51-5

3902

Antineoplastic Agents, Hormonal

Phase 3

Estrogens

Phase 3

Estrogen Receptor Antagonists

Phase 3

Estrogen Antagonists

Phase 3

Hormones

Phase 3

Hormone Antagonists

Phase 3

Aromatase Inhibitors

Phase 3

Docetaxel

Approved, Investigational

Phase 2

114977-28-5

148124

Darbepoetin alfa

Approved, Investigational

Phase 2

209810-58-2

Tamoxifen

Approved

Phase 2

10540-29-1, 54965-24-1

2733526

Donepezil

Approved

Phase 2

120014-06-4

3152

Epirubicin

Approved

Phase 2

56420-45-2

41867

Capecitabine

Approved, Investigational

Phase 2

154361-50-9

60953

Palbociclib

Approved, Investigational

Phase 2

571190-30-2

5330286

Estradiol

Approved, Investigational, Vet_approved

Phase 2

50-28-2

5757

Polyestradiol phosphate

Approved

Phase 2

28014-46-2

Neurotransmitter Agents

Phase 2

Cholinergic Agents

Phase 2

Antimitotic Agents

Phase 2

Tubulin Modulators

Phase 2

Epoetin Alfa

Phase 2

Hematinics

Phase 2

Nootropic Agents

Phase 2

Cholinesterase Inhibitors

Phase 2

Antimetabolites

Phase 2

Protein Kinase Inhibitors

Phase 2

Estradiol 3-benzoate

Phase 2

Estradiol 17 beta-cypionate

Phase 2

Cyclophosphamide

Approved, Investigational

Phase 1

50-18-0, 6055-19-2

2907

Doxorubicin

Approved, Investigational

Phase 1

23214-92-8

31703

Alkylating Agents

Phase 1

Antirheumatic Agents

Phase 1

Antineoplastic Agents, Alkylating

Phase 1

Immunosuppressive Agents

Phase 1

Immunologic Factors

Phase 1

Interventional clinical trials:

(show all 45)

#	Name	Status	NCT ID	Phase	Drugs
1	Evaluation of Adjuvant Endocrine Therapy for Operable ER-beta Positive, ER-alpha/PR Negative, Her-2 Negative Breast Cancer Patients	Unknown status	NCT02089854	Phase 4	Toremifene; Anastrozole
2	Does Anesthesia Technique Affect the Presence of Circulating Tumor Cells in Primary Breast Carcinoma? A Randomised Controlled Trial.	Completed	NCT02005770	Phase 4	Sevoflurane;Propofol
3	A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of FCN-437c Versus Placebo Combined With Fulvestrant ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer	Recruiting	NCT05438810	Phase 3	FCN-437c,Fulvestrant,Goserelin acetate;Placebo,Fulvestrant,Goserelin acetate
4	A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR-positive and HER2-negative Advanced Breast Cancer	Recruiting	NCT05439499	Phase 3	FCN-437c, Letrozole or anastrozole, Goserelin acetate;Placebo, Letrozole or anastrozole, Goserelin acetate
5	A Multicenter, Randomized, Double-blind Phase III Study：SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage，Female Breast Cancer	Enrolling by invitation	NCT04842617	Phase 3	SHR6390;placebo
6	Phase II Study of Dose-Dense TC (Docetaxel + Cyclophosphamide) With Pegfilgrastim Support for Adjuvant Therapy of pN0, pN1 or Nx Breast Cancer	Completed	NCT01671319	Phase 2	docetaxel + cyclophosphamide + pegfilgrastim
7	An Open-Label, Randomized Phase 2 Study to Validate a Patient Satisfaction Questionnaire for Anemia Treatment in Female Breast Cancer Patients Treated With Darbepoetin Alfa or Recombinant Human Erythropoietin for Anemia Due to Chemotherapy	Completed	NCT00120692	Phase 2	Darbepoetin Alfa;Recombinant Human Erythropoietin
8	A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Q-122 for the Treatment of Vasomotor Symptoms in Female Breast Cancer Patients/Survivors Taking Tamoxifen or an Aromatase Inhibitor	Completed	NCT03518138	Phase 2	Q-122;Placebo
9	A Feasibility Study of Donepezil in Female Breast Cancer Survivors With Self-Reported Cognitive Dysfunction Following Chemotherapy	Completed	NCT01466270	Phase 2	donepezil hydrochloride;Placebo
10	Differential Gene Regulation During Neoadjuvant Therapy Trial of Epirubicin/Cyclophosphamide (EC) vs Docetaxel/Capecitabine (DX) Regimens in Patients With Large ER-positive and ER-negative Breast Cancers: A Randomized Phase II Trial.	Completed	NCT01869192	Phase 2	Epirubicin;Cyclophosphamide;Docetaxel;Capecitabine
11	An Open-Label, Single-Arm, Phase 2 Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery	Completed	NCT03113825	Phase 2	AVB-620
12	Pilot Trial of Anastrozole and Palbociclib as First-Line Therapy and as Maintenance Therapy After First Line Chemotherapy in Hormone Receptor Positive, HER2-Negative Postmenopausal Metastatic Breast Cancer	Active, not recruiting	NCT02942355	Phase 2	anastrozole;Palbociclib
13	An Open Label, Phase 2 Pharmacokinetic Study of Pre-Surgical Intramuscular and Intraductal Fulvestrant in Women With Invasive Breast Cancer or DCIS Undergoing Mastectomy or Lumpectomy	Terminated	NCT02540330	Phase 2	Fulvestrant
14	A Phase II Study of High Dose Estradiol in Metastatic Triple Negative Breast Cancer	Terminated	NCT01083641	Phase 2	Estradiol
15	Image-guided Targeted Doxorubicin Delivery With Hyperthermia to Optimize Loco-regional Control in Breast Cancer. Phase I Feasibility Study of Hifu-Induced Hyperthermia, LTLD and Cyclophosphamide for Metastatic Breast Cancer	Recruiting	NCT03749850	Phase 1	LTLD;Cyclophosphamide
16	Effect of Yoga on Life Quality and Immunity in Breast Cancer Patients After Operation and or Chemotherapy	Unknown status	NCT02243163
17	Clinical Cohort of Individual Expectations, Side Effects, Quality of Life and Adherence in Postoperative Women With Estrogen Receptor Positive Breast Cancer During Endocrine Therapy	Unknown status	NCT02088710
18	A Prospective, Randomized, Controlled Trial to Compare the Effect of TIVA Propofol vs Sevoflurane Anaesthetic on Serumserum Biomarkers and on PBMCs in Patients Undergoing Breast Cancer Resection Surgery	Unknown status	NCT03005860		2,6-Diisopropylphenol;Fluoromethyl hexafluoroisopropyl ether;Fentanyl Citrate;Atracurium Besylate
19	Silent Breast Cancer A Study of the Disease Prevalence Held by Imaging Guided Biopsies in Autopsy Specimens	Unknown status	NCT02480933
20	Evaluating Female Sexual Dysfunction in Breast Cancer Patients After Mastectomy	Unknown status	NCT03153631
21	Clinical Application of Nocebo Research: Optimizing Expectations of Breast Cancer Patients to Prevent Nocebo Side Effects and Decrease of Quality of Life During Adjuvant Endocrine Therapy (DFG, NE 1635/2-1)	Unknown status	NCT01741883
22	Text for Health: Integrating Technology and Health Communication to Improve Health Outcomes (Part 2 of 2)	Completed	NCT04290585
23	Phase 1. Collect Samples of Breast Biopsy Patients Treated at the Hospital Radiology Service Maternal Perinatal Monica Pretelini	Completed	NCT01643148
24	Metabolic Syndrome and Female Breast Cancer: a Case-control Study in Southern Brazil	Completed	NCT02282592
25	Synbiotic Supplementation to Reduce Anxiety Symptoms in Female Breast Cancer Survivors and/or Their Female Relatives	Completed	NCT04784182
26	Effects of a Traditional Chinese Exercise Program- Tai Chi on Symptom Cluster of Fatigue-sleep Disturbance-depression in Female Breast Cancer Patients: a Preliminary Randomized Controlled Trial	Completed	NCT04190342
27	Trends of Mastectomy and Breast-Conserving Surgery and Related Factors in Female Breast Cancer Patients Treated at King Abdulaziz University Hospital, Jeddah, Saudi Arabia, 2009-2017	Completed	NCT03762642
28	The Effects of Auricular Acupressure on Chemotherapy-Induced Nausea and Vomiting in Female Breast Cancer Patients: A Pilot Randomized Controlled Trial	Completed	NCT02403037		Standard anti-emetic treatment (5-HT3 receptor antagonists and/or Dexamethasone)
29	Effect of Cryotherapy on Paclitaxel-Induced Peripheral Neuropathy of the Hand in Female Breast Cancer Patients: A Prospective Self-Controlled Study	Completed	NCT05138042
30	The Treatment For Recurrent Female Breast Cancer After Initial Endocrine Therapy Among Taiwanese Population	Completed	NCT02924584
31	Ultra-hypofractionated Adjuvant Radiotherapy After Breast Conserving Surgery in Breast Cancer Patients	Recruiting	NCT05586256
32	Exercise, Gut Microbiome, and Breast Cancer: Increasing Reach to Underserved Populations	Recruiting	NCT05000502
33	Efficacy of a Brief Intervention for Female Breast CANcer Based on Acceptance and Commitment Therapy (I-CAN-ACT) for Depression and Physical Pain: A 2-Arm Randomized Clinical Trial	Recruiting	NCT05374161
34	A Pilot Feasibility Study of a Gratitude Journaling Intervention to Enhance Well-being and Exercise Readiness in Older African American Female Breast Cancer Survivors	Recruiting	NCT05473026
35	Accelerated Partial Breast Irradiation (APBI) Using Stereotactic Body Radiation Therapy (SBRT): a Multicenter, Observational Clinical Trial	Recruiting	NCT04985032
36	Intervention to Promote Uptake of Cancer Risk Counseling for Underserved Latinas	Active, not recruiting	NCT01230346
37	Place of Comprehensive Geriatric Assessment (CGA) in Patients ≥ 75 Years Care, With Breast Cancer, After Screening With FOG (Oncology Geriatric Filter): Comparison Between CGA Before Surgery (Strategy A) vs. After Surgery (Strategy B)	Active, not recruiting	NCT03059875
38	Monocentric, Randomized Clinical Trial About the Effect of Yoga Practice on QOL, Physiological Distress and Fatigue, on Patients Affected by Breast Cancer Undergoing Adjuvant Radiotherapy	Active, not recruiting	NCT04775290
39	A Phase III, Randomized, Single Blind, Attention Controlled, Multi-center Study of the Effects of a Rehabilitation Intervention on Participation Restrictions of Female Breast Cancer Survivors	Active, not recruiting	NCT03915548
40	Diagnostic Value of Digital Breast Tomosymthesis for Breast Mass Lesions Characterization	Not yet recruiting	NCT04863833
41	Endocrine Therapy-Induced Alopecia Natural History Evaluation Among Female Breast Cancer Survivors	Not yet recruiting	NCT05612100
42	Breast Cancer in Young Women: Is it Different?	Suspended	NCT01320488
43	Acupuncture for Joint Symptoms in Patients With Breast Cancer: A Randomised Controlled Trial	Terminated	NCT03836872
44	The Process and Outcomes of Treatment Decision-Making Communication Between Oncologists and Newly Diagnosed Female Breast-Cancer Patients	Terminated	NCT00891969
45	The Efficacy of Reduced-exertion High-intensity Interval Training for Improving Health and Well-being in Newly Diagnosed Female Breast Cancer Patients	Withdrawn	NCT03176888

Search NIH Clinical Center for Female Breast Cancer

Sources

Genetic Tests for Female Breast Cancer

Sources

Anatomical Context for Female Breast Cancer

Organs/tissues related to Female Breast Cancer:

MalaCards : Breast, Lymph Node, Prostate, Lung, Bone, Bone Marrow, Brain

Sources

Publications for Female Breast Cancer

Articles related to Female Breast Cancer:

(show top 50) (show all 2904)

#	Title	Authors	PMID	Year
1	Typhoid vaccine does not impact feelings of social connection or social behavior in a randomized crossover trial among middle-aged female breast cancer survivors. ⁶²	Madison AA...Kiecolt-Glaser JK	36208853	2023
2	Prognostic Predictors of Mortality in Male Breast Cancer: Outcomes in an Urban Population. ⁶²	Sogunro OA...Son JD	36182676	2023
3	The preventability of cancer in Europe: A quantitative assessment of avoidable cancer cases across 17 cancer sites and 38 countries in 2020. ⁶²	Cabasag CJ...Soerjomataram I	36323048	2022
4	Cancers Among Adolescents and Young Adults in Maine 2001-2017: A Descriptive Analysis and Model for Future Studies. ⁶²	Speckhart SA	35856871	2022
5	Retrospective analysis: 5509 cases of "totally implantable venous access port systems implantation (TIVAPS) depth" assisted by digital radiography. ⁶²	Chen K...Lu P	35660962	2022
6	Cohort profile: Risk and risk factors for female breast cancer after treatment for childhood and adolescent cancer: an internationally pooled cohort. ⁶²	Wang Y...Teepen JC	36344003	2022
7	Cancer risks associated with heterozygous ATM loss of function and missense pathogenic variants based on multigene panel analysis. ⁶²	Laitman Y...Friedman E	36094610	2022
8	Treatment-related thoracic soft tissue sarcomas in US breast cancer survivors: a retrospective cohort study. ⁶²	Veiga LHS...Berrington de Gonzalez A	36240805	2022
9	Clinicopathological Features of Breast Cancer in Relation to Exposure of Cycling Reproductive Hormones: A Multicenter Retrospective Study of 14,731 Patients Diagnosed with Invasive Breast Cancer. ⁶²	Sun J...Yang D	36447408	2022
10	Efficacy of neoadjuvant chemotherapy in male breast cancer compared with female breast cancer. ⁶²	Leone JP...Lin NU	36069365	2022
11	Gynecomastia and Malignancy: A Case of Male Invasive Ductal Breast Carcinoma Treated with Neoadjuvant Chemotherapy. ⁶²	Mekheal E...Maroules M	36335424	2022
12	Cancer situation in China: what does the China cancer map indicate from the first national death survey to the latest cancer registration? ⁶²	Feng R...Ye W	36397729	2022
13	Associations between circulating obesity-related biomarkers and prognosis in female breast cancer survivors: a systematic review of observational data in women enrolled in lifestyle intervention trials. ⁶²	Meyer D...Hauner D	36401194	2022
14	Molecular characterization of early breast cancer onset to understand disease phenotypes in African patients. ⁶²	Tonouo PD...Lueong SS	36352274	2022
15	The experiences and perceptions of female breast cancer patients regarding weight management during and after treatment for oestrogen-receptor positive disease: a qualitative study. ⁶²	Jm S...C W	36401195	2022
16	Psychometric assessment of the Concerns about Late Effects in Oncology Questionnaire (CLEO) among female breast cancer survivors. ⁶²	Chen J...Shaw J	35989203	2022
17	Improving resistance training prescription through the load-velocity relationship in breast cancer survivors: The case of the leg-press exercise. ⁶²	Diez-Fernandez DM...Soriano-Maldonado A	34353234	2022
18	Breast Cancer Statistics, 2022. ⁶²	Giaquinto AN...Siegel RL	36190501	2022
19	Milk consumption and risk of twelve cancers: A large-scale observational and Mendelian randomisation study. ⁶²	Lumsden AL...Hypponen E	36473423	2022
20	Cardiotoxicity in cancer patients treated with chemotherapy: A systematic review. ⁶²	Lima MAC...Oliveira HF	36475028	2022
21	Clinicopathological features of male patients with breast cancer based on a nationwide registry database in Japan. ⁶²	Shimomura A...Jinno H	35733033	2022
22	Regional inequalities of tumour size at diagnosis in Germany: An ecological study in eight federal states. ⁶²	Jaehn P...Holmberg C	35723083	2022
23	Protocol for the postoperative radiotherapy in N1 breast cancer patients (PORT-N1) trial, a prospective multicenter, randomized, controlled, non-inferiority trial of patients receiving breast-conserving surgery or mastectomy. ⁶²	Lee TH...Shin KH	36384573	2022
24	Sexual Health after a Breast Cancer Diagnosis: Addressing a Forgotten Aspect of Survivorship. ⁶²	Vegunta S...Mussallem DM	36431200	2022
25	Psychosocial characteristics of chronic pain in cancer survivors referred to an Australian multidisciplinary pain clinic. ⁶²	Glare PA...Nicholas MK	35661330	2022
26	Factors associated with the development of extrahepatic malignancy in patients with nonalcoholic fatty liver disease: a single-center longitudinal study. ⁶²	Gumussoy M...Idilman R	36170687	2022
27	Adjuvant Treatment for Breast Cancer Patients Using Individualized Neoantigen Peptide Vaccination-A Retrospective Observation. ⁶²	Zelba H...Biskup S	36366390	2022
28	Co-designed weight management intervention for women recovering from oestrogen-receptor positive breast cancer. ⁶²	Saxton JM...Wilson C	36418985	2022
29	2D Hetero-Nanoconstructs of Black Phosphorus for Breast Cancer Theragnosis: Technological Advancements. ⁶²	Soman S...Mutalik S	36421127	2022
30	Endoscopy-assisted latissimus dorsi muscle flap harvesting technique for immediate breast reconstruction. ⁶²	Cha Y...Lee S	36328867	2022
31	Breast cancer: age incidence, hormone receptor status and family history in Najaf, Iraq. ⁶²	Khalaf H...Abu A	36420288	2022
32	The impact of APOE and smoking history on cognitive function in older, long-term breast cancer survivors. ⁶²	Ahles TA...Hurria A	36279076	2022
33	Circulating LncRNAs landscape as potential biomarkers in breast cancer. ⁶²	Pourramezan Z...Oloomi M	36274054	2022
34	Marked Reduction in the Risk of Dementia in Patients with Breast Cancer: A Nationwide Population-Based Cohort Study. ⁶²	Oh J...Yoon CI	36265508	2022
35	Exercise Leg Blood Flow Is Preserved in Long-term Breast Cancer Survivors Previously Treated With Anthracycline Chemotherapy. ⁶²	Beaudry RI...Haykowsky MJ	36223443	2022
36	Access to Surgical Treatment for Breast Cancer in the Philippines. ⁶²	Co LMB...Ang CDU	35913672	2022
37	Early alterations in cortical morphology after neoadjuvant chemotherapy in breast cancer patients: A longitudinal magnetic resonance imaging study. ⁶²	Zhou X...Zhang J	35665982	2022
38	Diagnostic tools should be used for the diagnosis of chemotherapy induced peripheral neuropathy in breast cancer patients receiving taxanes. ⁶²	van Haren F...Steegers M	34687287	2022
39	Dilemma: Disclosure Experience Among Young Female Breast Cancer Survivors in China. ⁶²	Liu X...Zhu P	34962155	2022
40	Sexual Perception in Spanish Female Breast Cancer Survivors. Cross-Sectional Survey. ⁶²	Torres-Balanza S...Sempere-Rubio N	36357269	2022
41	A stabilized spatiotemporal kriging method for disease mapping and application to male oral cancer and female breast cancer in Taiwan. ⁶²	Tsai DR...Lee WC	36229788	2022
42	Temporal trends in social security benefits for female breast cancer in Brazil. ⁶²	Girardi FA...Guerra MR	36134809	2022
43	Presentation and management of female breast cancer in Egypt. ⁶²	Rostom Y...Mahmoud N	36382727	2022
44	Comparison of female breast cancer between Russia and Germany: A population-based study on time trends and stage at diagnosis. ⁶²	Mahanani MR...Winkler V	35841762	2022
45	Six case reports of NTHL1-associated tumor syndrome further support it as a multi-tumor predisposition syndrome. ⁶²	Weatherill CB...Darabi S	36196035	2022
46	Low-Dose Extrapolation Factors Implied by Mortality and Incidence Data from the Japanese Atomic Bomb Survivor Life Span Study Data. ⁶²	Little MP...Hamada N	36161867	2022
47	Eating Earlier and More Frequently Is Associated With Better Diet Quality in Female Brazilian Breast Cancer Survivors Using Tamoxifen. ⁶²	Lima MTM...Paiva Maia YC	35533872	2022
48	Presentation, Diagnosis and Treatment Delays in Breast Cancer Care and Their Associations in Sri Lanka, a Low-resourced Country. ⁶²	Hewage SA...Gunawardena N	35672184	2022
49	Synthesis and comparative evaluation of ¹⁷⁷Lu-labeled PEG and non-PEG variant peptides as HER2-targeting probes. ⁶²	Sharma AK...Satpati D	36127494	2022
50	The mortalities of female-specific cancers in China and other countries with distinct socioeconomic statuses: A longitudinal study. ⁶²	Jiang D...Cao G	36130684	2022

Sources

Genes for Female Breast Cancer

Genes related to Female Breast Cancer (0 elite genes):

(show all 29)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	PGR	Progesterone Receptor	Protein Coding	14.32	DISEASES inferred ¹⁴ ¹⁴
2	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	13.96	DISEASES inferred ¹⁴ ¹⁴
3	ESR1	Estrogen Receptor 1	Protein Coding	13.71	DISEASES inferred ¹⁴ ¹⁴
4	BRCA2	BRCA2 DNA Repair Associated	Protein Coding	12.12	DISEASES inferred ¹⁴ ¹⁴
5	BRCA1	BRCA1 DNA Repair Associated	Protein Coding	12.1	DISEASES inferred ¹⁴ ¹⁴
6	TP53	Tumor Protein P53	Protein Coding	10.98	DISEASES inferred ¹⁴ ¹⁴
7	CYP19A1	Cytochrome P450 Family 19 Subfamily A Member 1	Protein Coding	10.21	DISEASES inferred ¹⁴ ¹⁴
8	AR	Androgen Receptor	Protein Coding	10.17	DISEASES inferred ¹⁴ ¹⁴
9	PIP	Prolactin Induced Protein	Protein Coding	9.38	DISEASES inferred ¹⁴ ¹⁴
10	EGFR	Epidermal Growth Factor Receptor	Protein Coding	9.03	DISEASES inferred ¹⁴ ¹⁴
11	KLK3	Kallikrein Related Peptidase 3	Protein Coding	8.92	DISEASES inferred ¹⁴ ¹⁴
12	BCL2	BCL2 Apoptosis Regulator	Protein Coding	8.82	DISEASES inferred ¹⁴ ¹⁴
13	GATA3	GATA Binding Protein 3	Protein Coding	8.73	DISEASES inferred ¹⁴ ¹⁴
14	KRT5	Keratin 5	Protein Coding	8.43	DISEASES inferred ¹⁴ ¹⁴
15	CTSD	Cathepsin D	Protein Coding	8.32	DISEASES inferred ¹⁴ ¹⁴
16	MLH1	MutL Homolog 1	Protein Coding	8.31	DISEASES inferred ¹⁴ ¹⁴
17	TOP2A	DNA Topoisomerase II Alpha	Protein Coding	8.14	DISEASES inferred ¹⁴ ¹⁴
18	ANKRD30A	Ankyrin Repeat Domain 30A	Protein Coding	8.12	DISEASES inferred ¹⁴ ¹⁴
19	CDK4	Cyclin Dependent Kinase 4	Protein Coding	8.03	DISEASES inferred ¹⁴ ¹⁴
20	ESR2	Estrogen Receptor 2	Protein Coding	7.99	DISEASES inferred ¹⁴ ¹⁴
21	CD44	CD44 Molecule (Indian Blood Group)	Protein Coding	7.94	DISEASES inferred ¹⁴ ¹⁴
22	CCND1	Cyclin D1	Protein Coding	7.87	DISEASES inferred ¹⁴ ¹⁴
23	PLEKHB1	Pleckstrin Homology Domain Containing B1	Protein Coding	7.78	DISEASES inferred ¹⁴ ¹⁴
24	CDV3	CDV3 Homolog	Protein Coding	7.41	DISEASES inferred ¹⁴ ¹⁴
25	KRT19	Keratin 19	Protein Coding	7.33	DISEASES inferred ¹⁴ ¹⁴
26	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	7.3	DISEASES inferred ¹⁴ ¹⁴
27	ERBB3	Erb-B2 Receptor Tyrosine Kinase 3	Protein Coding	7.29	DISEASES inferred ¹⁴ ¹⁴
28	CYP2C19	Cytochrome P450 Family 2 Subfamily C Member 19	Protein Coding	7.29	DISEASES inferred ¹⁴ ¹⁴
29	KRT14	Keratin 14	Protein Coding	7.18	DISEASES inferred ¹⁴ ¹⁴

Sources

Variations for Female Breast Cancer

Sources

Expression for Female Breast Cancer

Search GEO for disease gene expression data for Female Breast Cancer.

Sources

Pathways for Female Breast Cancer

Pathways related to Female Breast Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 56)

#	Super pathways	Score	Top Affiliating Genes
1	Gene expression (Transcription) ⁶⁶ Show member pathways Generic Transcription Pathway ⁶⁶ RNA Polymerase II Transcription ⁶⁶	14.06	AR BRCA1 CDK4 EGFR ERBB2 ESR1
2	ERK Signaling ⁶⁴ Show member pathways ILK Signaling ⁶⁴ MAPK Signaling ⁶⁴ Molecular Mechanisms of Cancer ⁶⁴ Rho Family GTPases ⁶⁴	13.81	BCL2 BRCA1 CDK4 EGFR ERBB2 ESR1
3	Disease ⁶⁶ Show member pathways Infectious disease ⁶⁶	13.78	TP53 MLH1 ESR2 ESR1 ERBB2 EGFR
4	Signal Transduction ⁶⁶	13.69	AR BCL2 CDK4 CTSD EGFR ERBB2
5	GPCR Pathway ⁶⁴ Show member pathways Breast Cancer Regulation by Stathmin1 ⁶⁴ Estrogen Pathway ⁶⁴ NFAT in Immune Response ⁶⁴ P2Y Receptor Signaling ⁶⁴ Pancreatic Adenocarcinoma ⁶⁴ Paxillin Interactions ⁶⁴ Ras Pathway ⁶⁴	13.68	TP53 ESR2 ESR1 ERBB2 EGFR CDK4
6	ESR-mediated signaling ⁶⁶ Show member pathways Estrogen-dependent gene expression ⁶⁶ RUNX1 regulates estrogen receptor mediated transcription ⁶⁶ Signaling by Nuclear Receptors ⁶⁶	12.95	BCL2 CTSD EGFR ESR1 ESR2 GATA3
7	Signaling by Receptor Tyrosine Kinases ⁶⁶	12.82	PGR ESR1 ERBB2 EGFR CTSD
8	Deubiquitination ⁶⁶ Show member pathways Ub-specific processing proteases ⁶⁶	12.81	TP53 GATA3 ESR1 BRCA1 AR
9	Malignant pleural mesothelioma ⁷⁴	12.68	TP53 EGFR CDK4 BRCA1 BCL2
10	Endometrial cancer ⁷⁴ Show member pathways Chromosomal and microsatellite instability in colorectal cancer ⁷⁴ Melanoma ⁷⁴ Non-small cell lung cancer ⁷⁴ Pancreatic adenocarcinoma pathway ⁷⁴ Signal transduction PTEN pathway ²²	12.6	TP53 MLH1 ERBB2 EGFR CDK4 BRCA2
11	DNA Damage ³	12.48	TP53 TOP2A MLH1 CDK4 BRCA2 BRCA1
12	Chks in Checkpoint Regulation ⁶⁴ Show member pathways DNA Repair Mechanisms ⁶⁴ Estrogen-mediated S-Phase Entry ⁶⁴ G2-M Phase Transition ⁶⁴ SREBP Proteolysis ⁶⁴	12.48	TP53 ESR2 ESR1 CDK4 BRCA2 BRCA1
13	Hepatocyte growth factor receptor signaling ⁷⁴ Show member pathways Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1 ²² Apoptosis and survival NGF signaling pathway ²² Apoptosis and survival Role of CDK5 in neuronal death and survival ²² Development HGF signaling pathway ²² Development Neurotrophin family signaling ²² Drug-mediated inhibition of MET activation ⁶⁶ MET activates PTPN11 ⁶⁶ MET activates STAT3 ⁶⁶ PLC-gamma1 signalling ⁶⁶ Trk receptor signaling mediated by PI3K and PLC-gamma ⁶¹ TRKA activation by NGF ⁶⁶	12.45	TP53 ESR1 ERBB2 BCL2
14	NF-kappaB Pathway ⁷⁰ Show member pathways Akt Pathway ⁷⁰ Apoptosis Pathway ⁷⁰	12.42	TP53 ERBB2 EGFR BCL2
15	Development Dopamine D2 receptor transactivation of EGFR ²² Show member pathways Chemotaxis CXCR4 signaling pathway ²² Development Alpha-2 adrenergic receptor activation of ERK ²² Extra-nuclear estrogen signaling ⁶⁶	12.4	ESR2 ESR1 EGFR BCL2
16	Cell cycle Regulation of G1/S transition (part 1) ²² Show member pathways Cell cycle ESR1 regulation of G1/S transition ²² Cell cycle Role of SCF complex in cell cycle regulation ²² Immune response MIF-JAB1 signaling ²² Mitotic Roles of Polo Like Kinases ⁶⁴	12.35	PGR ESR1 CDK4 BRCA1
17	Development Ligand-independent activation of ESR1 and ESR2 ²² Show member pathways Transcription CREB pathway ²² Transcription PPAR Pathway ²²	12.31	ESR2 ESR1 ERBB2 EGFR
18	p53 Signaling ⁶⁴ Show member pathways p53 Pathway ⁶⁷	12.19	TP53 CDK4 BRCA1 BCL2
19	MAPK Signaling: Mitogens ⁶⁵ Show member pathways Akt Signaling Pathway ⁶⁵	12.18	TP53 ERBB2 EGFR CDK4 BCL2
20	Transcription Androgen Receptor nuclear signaling ²² Show member pathways Translation Non-genomic (rapid) action of Androgen Receptor ²²	12.1	KLK3 ERBB2 EGFR AR
21	Signaling by ERBB4 ⁶⁶ Show member pathways Downregulation of ERBB4 signaling ⁶⁶ ErbB4 signaling events ⁶¹ Nuclear signaling by ERBB4 ⁶⁶	12.05	PGR ESR1 ERBB2 EGFR
22	Breast cancer pathway ⁷⁴ Show member pathways Embryonic stem cell pluripotency pathways ⁷⁴	12.04	TP53 PGR ESR2 ESR1 ERBB2 EGFR
23	Direct p53 effectors ⁶¹	12.03	TP53 MLH1 EGFR CTSD BCL2
24	Nuclear receptors ⁷⁴ Show member pathways Nuclear Receptor transcription pathway ⁶⁶ SUMOylation of intracellular receptors ⁶⁶	11.99	PGR ESR2 ESR1 AR
25	TGF-beta Signaling Pathways ⁶⁵	11.88	ESR2 ESR1 AR
26	Small cell lung cancer ⁷⁴	11.88	TP53 CDK4 BCL2
27	Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors ⁶⁶ Show member pathways Activation of the TFAP2 (AP-2) family of transcription factors ⁶⁶ Negative regulation of activity of TFAP2 (AP-2) family transcription factors ⁶⁶ TFAP2 (AP-2) family regulates transcription of cell cycle factors ⁶⁶ TFAP2 (AP-2) family regulates transcription of growth factors and their receptors ⁶⁶ TFAP2 (AP-2) family regulates transcription of other transcription factors ⁶⁶ TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation ⁶⁶	11.84	ESR1 ERBB2 EGFR
28	Retinoblastoma gene in cancer ⁷⁴	11.82	TP53 TOP2A CDK4
29	BRCA1 Pathway ⁶⁴ Show member pathways Fanconi's Anaemia Pathway ⁶⁴	11.8	TP53 BRCA2 BRCA1
30	DNA IR-damage and cellular response via ATR ⁷⁴	11.79	TP53 MLH1 BRCA2 BRCA1
31	Glucocorticoid receptor regulatory network ⁶¹	11.76	TP53 KRT5 GATA3
32	Regulation of nuclear SMAD2/3 signaling ⁶¹	11.74	GATA3 ESR1 AR
33	Head and neck squamous cell carcinoma ⁷⁴	11.73	TP53 ERBB2 EGFR CDK4
34	Validated targets of C-MYC transcriptional repression ⁶¹	11.65	ERBB2 BRCA1 BCL2
35	Pathways affected in adenoid cystic carcinoma ⁷⁴	11.64	TP53 ERBB2 BRCA1
36	Coregulation of Androgen receptor activity ⁶¹	11.63	KLK3 BRCA1 AR
37	ATF-2 transcription factor network ⁶¹	11.6	ESR1 CDK4 BRCA1 BCL2
38	Validated nuclear estrogen receptor alpha network ⁶¹	11.53	BRCA1 CTSD ESR1 ESR2 PGR
39	Validated transcriptional targets of deltaNp63 isoforms ⁶¹	11.51	TOP2A KRT5 BRCA2
40	DNA damage_ATM/ATR regulation of G1/S checkpoint ²²	11.47	BRCA1 CDK4 TP53
41	Integrated breast cancer pathway ⁷⁴	11.46	TP53 ESR1 EGFR CYP19A1 CDK4 BRCA2
42	Doxorubicin Pathway, Pharmacokinetics ⁶⁰ Show member pathways Doxorubicin Pathway (Cancer Cell), Pharmacodynamics ⁶⁰	11.42	TP53 TOP2A MLH1
43	Bladder cancer ⁷⁴	11.41	TP53 ERBB2 EGFR CDK4
44	LKB1 signaling events ⁶¹	11.38	TP53 ESR1 CTSD
45	FOXM1 transcription factor network ⁶¹	11.36	BRCA2 CDK4 ESR1
46	Integrated cancer pathway ⁷⁴	11.36	TP53 CDK4 BRCA1 BCL2
47	FOXA1 transcription factor network ⁶¹	11.33	KLK3 ESR1 BRCA1 AR
48	GADD45 Pathway ⁶⁴	11.3	TP53 CDK4 BRCA1
49	Gastric cancer network 2 ⁷⁴	11.28	TP53 TOP2A EGFR
50	Apoptosis and survival_Anti-apoptotic action of nuclear ESR1 and ESR2 ²²	11.21	ESR2 ESR1 BCL2

Sources

GO Terms for Female Breast Cancer

Cellular components related to Female Breast Cancer according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	protein-containing complex	GO:0032991	9.6	TP53 TOP2A KLK3 ESR1 EGFR CDK4
2	nuclear ubiquitin ligase complex	GO:0000152	9.46	BRCA2 BRCA1
3	condensed chromosome	GO:0000793	9.26	TOP2A MLH1 BRCA1

Biological processes related to Female Breast Cancer according to GeneCards Suite gene sharing:

(show all 25)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of DNA-templated transcription	GO:0045893	10.31	TP53 GATA3 ESR2 ESR1 EGFR BRCA2
2	cellular response to DNA damage stimulus	GO:0006974	10.21	TP53 TOP2A MLH1 BRCA2 BRCA1 BCL2
3	negative regulation of cell growth	GO:0030308	10.17	TP53 ESR2 BRCA1 BCL2
4	positive regulation of gene expression	GO:0010628	10.15	AR BRCA1 ERBB2 GATA3 PGR PIP
5	male gonad development	GO:0008584	10.13	GATA3 ESR1 BCL2 AR
6	cellular response to estradiol stimulus	GO:0071392	10.08	ESR2 ESR1 EGFR
7	cellular response to ionizing radiation	GO:0071479	10.03	BRCA1 BRCA2 TP53
8	T cell differentiation in thymus	GO:0033077	10	TP53 GATA3 BCL2
9	cell population proliferation	GO:0008283	9.95	BCL2 BRCA2 EGFR GATA3 TP53
10	negative regulation of reactive oxygen species metabolic process	GO:2000378	9.93	TP53 BRCA1 BCL2
11	intracellular estrogen receptor signaling pathway	GO:0030520	9.91	ESR2 ESR1 AR
12	B cell lineage commitment	GO:0002326	9.89	BCL2 TP53
13	positive regulation of RNA polymerase II transcription preinitiation complex assembly	GO:0045899	9.88	ESR1 TP53
14	morphogenesis of an epithelial fold	GO:0060571	9.85	EGFR AR
15	negative regulation of mammary gland epithelial cell proliferation	GO:0033600	9.84	GATA3 BRCA2
16	tertiary branching involved in mammary gland duct morphogenesis	GO:0060748	9.8	PGR AR
17	uterus development	GO:0060065	9.8	GATA3 ESR1 CYP19A1
18	intrinsic apoptotic signaling pathway in response to DNA damage	GO:0008630	9.8	MLH1 BRCA2 BRCA1 BCL2
19	chordate embryonic development	GO:0043009	9.79	BRCA2 BRCA1
20	T cell lineage commitment	GO:0002360	9.79	TP53 BCL2
21	immune system development	GO:0002520	9.76	BCL2 GATA3
22	positive regulation of miRNA transcription	GO:1902895	9.63	AR EGFR GATA3 TP53
23	positive regulation of miRNA maturation	GO:1903800	9.62	TP53 EGFR
24	response to gamma radiation	GO:0010332	9.56	TP53 GATA3 BRCA2 BCL2
25	intracellular steroid hormone receptor signaling pathway	GO:0030518	9.23	PGR ESR2 ESR1 AR

Molecular functions related to Female Breast Cancer according to GeneCards Suite gene sharing:

(show all 12)

#	Name	GO ID	Score	Top Affiliating Genes
1	identical protein binding	GO:0042802	10.49	BCL2 BRCA1 BRCA2 EGFR ERBB2 ESR1
2	chromatin binding	GO:0003682	10.29	TP53 TOP2A MLH1 ESR1 EGFR AR
3	sequence-specific DNA binding	GO:0043565	9.98	PGR GATA3 ESR2 ESR1 BCL2 AR
4	ATPase binding	GO:0051117	9.97	AR EGFR ESR1 PGR
5	protein phosphatase binding	GO:0019903	9.95	TP53 ERBB2 EGFR BCL2
6	nuclear receptor activity	GO:0004879	9.86	PGR ESR2 ESR1 AR
7	estrogen response element binding	GO:0034056	9.78	ESR2 ESR1
8	nuclear estrogen receptor activity	GO:0030284	9.76	ESR2 ESR1
9	transcription coactivator binding	GO:0001223	9.76	PGR GATA3 ESR1 AR
10	nuclear steroid receptor activity	GO:0003707	9.72	PGR ESR2 ESR1
11	enzyme binding	GO:0019899	9.58	TP53 TOP2A PGR MLH1 ESR2 ESR1
12	steroid binding	GO:0005496	9.56	AR ESR1 ESR2 PGR